Skip to main content
Explore URMC

menu

Phase 3 Alogliptin Pediatric Study

Research Question:
Does the drug alogliptin help children age 10-17 with type 2 diabetes?

Basic Study Information

Purpose:
This study will evaluate the efficacy and safety of alogliptin 25 mg once daily (QD) compared to placebo when administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin in pediatric participants 10 to 17 years of age with type 2 diabetes mellitus (T2DM).

Location: University of Rochester

Study Contact Information

Study Coordinator: Takeda Study Registration Call Center
Email: medicalinformation@tpna.com

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search